inorganic hydroxy compound - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	inorganic hydroxy compound	go back to main search page
Accession:	CHEBI:52625	browse the term
Synonyms:	related_synonym:	inorganic hydroxides

show annotations for term's descendants Sort by:
Rat (766) Mouse (780) Human (781) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (4) Green Monkey (0) Naked Mole-rat (0) All
Genes (766)

ammonium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Ammonium Hydroxide results in increased expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

heme oxygenase 1

multiple interactions
increases expression

Ammonium Hydroxide results in increased expression of and results in increased activity of HMOX1 protein
Ammonium Hydroxide results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

Augmentin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of ABCB11 mRNA

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

aldo-keto reductase family 1 member B10

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

caspase 3

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cytochrome c, somatic

increases secretion

Amoxicillin-Potassium Clavulanate Combination results in increased secretion of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

fibroblast growth factor 19

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

glucose-6-phosphate dehydrogenase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of G6PD mRNA

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glutamate-cysteine ligase, catalytic subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gamma-glutamyltransferase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

increases activity

Amoxicillin-Potassium Clavulanate Combination results in increased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione-disulfide reductase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

malic enzyme 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

solute carrier family 10 member 1

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 51 member A

decreases expression

Amoxicillin-Potassium Clavulanate Combination results in decreased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

solute carrier family 7 member 11

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

transketolase

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TKT mRNA

NCBI chr16:5,723,764...5,748,702
Ensembl chr16:5,723,762...5,748,698

G

thioredoxin reductase 1

increases expression

Amoxicillin-Potassium Clavulanate Combination results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

calcium dihydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alkaline phosphatase, biomineralization associated

increases expression

Calcium Hydroxide results in increased expression of ALPL mRNA

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

collagen type I alpha 1 chain

increases expression

Calcium Hydroxide results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

estrogen receptor 1

increases expression

Calcium Hydroxide results in increased expression of ESR1 mRNA

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

DNA polymerase gamma, catalytic subunit

affects expression

Calcium Hydroxide affects the expression of POLG mRNA

NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567

G

DNA polymerase gamma 2, accessory subunit

affects expression

Calcium Hydroxide affects the expression of POLG2 mRNA

NCBI chr10:91,712,586...91,723,008
Ensembl chr10:91,712,586...91,723,008

G

transcription factor A, mitochondrial

affects expression

Calcium Hydroxide affects the expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

transient receptor potential cation channel, subfamily V, member 1

increases expression

Calcium Hydroxide results in increased expression of TRPV1 mRNA

NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513

carbidopa

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein]
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]

PMID:34560070 PMID:35202708

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]

PMID:34560070 PMID:35202708

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

PMID:34560070 PMID:35202708

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]

PMID:34560070 PMID:35202708

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catechol-O-methyltransferase

increases methylation

COMT protein results in increased methylation of Carbidopa

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

dopa decarboxylase

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA]
Carbidopa binds to and results in decreased activity of DDC protein

PMID:35151785 PMID:35202708

NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208

G

dynamin 1-like

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

fission, mitochondrial 1

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

glutamic--pyruvic transaminase

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 1 beta

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

monoamine oxidase A

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]

PMID:34560070 PMID:35202708

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitofusin 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]]

NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640

G

mitochondrially encoded ATP synthase membrane subunit 6

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]

NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599

G

mitochondrially encoded cytochrome b

multiple interactions

Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]

NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]]

NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

synuclein alpha

multiple interactions

[Levodopa co-treated with Carbidopa] inhibits the reaction [Reserpine results in increased expression of SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

signal transducer and activator of transcription 3

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tumor necrosis factor

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein]
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tryptophan hydroxylase 1

multiple interactions

[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein]

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

ceftazidime pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Ceftazidime

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

dihydrofolate reductase

decreases activity

Ceftazidime results in decreased activity of DHFR protein

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

heat shock transcription factor 1

decreases activity

Ceftazidime results in decreased activity of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 10

multiple interactions

Ceftazidime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

cilazapril monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

affects response to substance

ACE gene polymorphism affects the susceptibility to Cilazapril

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adiponectin, C1Q and collagen domain containing

increases expression

Cilazapril results in increased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

angiotensin II receptor, type 1a

multiple interactions

[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

angiotensin II receptor, type 2

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]

NCBI chr X:112,119,876...112,124,060
Ensembl chr X:112,120,228...112,124,057

G

fibroblast growth factor 2

decreases expression

Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

natriuretic peptide A

multiple interactions
affects secretion

[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein
Cilazapril affects the secretion of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

renin

increases activity

Cilazapril results in increased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 15 member 1

multiple interactions

Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine]

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545

G

solute carrier family 15 member 2

multiple interactions

Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine]

NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225

G

transforming growth factor, beta 1

multiple interactions

[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

dideuterium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT2 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of AKT3 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

BCL2 associated X, apoptosis regulator

increases expression

Deuterium Oxide results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

beclin 1

increases expression
multiple interactions

Deuterium Oxide results in increased expression of BECN1 protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

caspase 3

increases cleavage

Deuterium Oxide results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Acetylcysteine inhibits the reaction [Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Deuterium Oxide results in increased expression of and results in increased lipidation of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

Deuterium Oxide results in decreased phosphorylation of MTOR protein
Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions
decreases phosphorylation

Acetylcysteine inhibits the reaction [Deuterium Oxide results in decreased phosphorylation of PIK3R1 protein]

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

Antimony Potassium Tartrate results in decreased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily C member 1

affects response to substance
decreases response to substance
increases secretion
multiple interactions

ABCC1 protein affects the susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate
ABCC1 protein results in increased secretion of Antimony Potassium Tartrate
[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate; Glutathione affects the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Antimony Potassium Tartrate]; verlukast inhibits the reaction [ABCC1 protein results in increased secretion of Antimony Potassium Tartrate]

PMID:10025956 PMID:10348353 PMID:11278867 PMID:12018890 PMID:12731862

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of ABCC2 mRNA; Antimony Potassium Tartrate results in increased expression of ABCC2 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC2 mRNA

PMID:11408547 PMID:32076005

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

acid phosphatase 2, lysosomal

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACP2 mRNA

NCBI chr 3:77,175,022...77,185,180
Ensembl chr 3:77,175,895...77,185,680

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

adrenomedullin

increases expression

Antimony Potassium Tartrate results in increased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

aldo-keto reductase family 1 member B1

decreases expression
increases expression

Antimony Potassium Tartrate results in decreased expression of AKR1B1 mRNA
Antimony Potassium Tartrate results in increased expression of AKR1B1 mRNA

PMID:17547211 PMID:28713220

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA

PMID:28713220 PMID:32076005

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

aldo-keto reductase family 1, member C2

increases expression

Antimony Potassium Tartrate results in increased expression of AKR1C2 protein

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of AKR1C3 mRNA; Antimony Potassium Tartrate results in increased expression of AKR1C3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1C3 mRNA

PMID:28713220 PMID:32076005

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

aldehyde dehydrogenase 3 family, member B2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,250,260...201,264,699
Ensembl chr 1:201,253,157...201,264,705

G

aldehyde dehydrogenase 3 family, member B3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ALDH3B2 mRNA

NCBI chr 1:201,193,832...201,201,666
Ensembl chr 1:201,187,962...201,250,204

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ALDH6A1 mRNA

NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656

G

aldolase, fructose-bisphosphate A

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOA mRNA

NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182

G

aldolase, fructose-bisphosphate C

increases expression

Antimony Potassium Tartrate results in increased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

androgen receptor

increases phosphorylation

Antimony Potassium Tartrate results in increased phosphorylation of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ATPase plasma membrane Ca2+ transporting 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

alpha-2-glycoprotein 1, zinc-binding

decreases expression

Antimony Potassium Tartrate results in decreased expression of AZGP1 mRNA

NCBI chr12:16,930,990...16,939,333
Ensembl chr12:16,931,024...16,939,091

G

BARX homeobox 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BARX2 mRNA

NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013

G

BCL2 associated X, apoptosis regulator

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

666-15 compound promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 6

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]; Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

basic transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTF3 mRNA

NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879

G

BTG anti-proliferation factor 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calmodulin-like 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of CALML5 mRNA

NCBI chr17:66,394,433...66,395,352

G

calreticulin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

caspase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

carbonyl reductase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CBR1 mRNA

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

cyclin B2

increases expression

Antimony Potassium Tartrate results in increased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 3

increases expression

Antimony Potassium Tartrate results in increased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

complement factor B

decreases expression

Antimony Potassium Tartrate results in decreased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

CDC28 protein kinase regulatory subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of CKS2 mRNA

NCBI chr17:13,570,611...13,575,770

G

calmegin

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLGN mRNA

NCBI chr19:24,695,140...24,728,542
Ensembl chr19:24,696,875...24,728,758

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

Antimony Potassium Tartrate results in decreased expression of CLPTM1 mRNA

NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092

G

CCHC-type zinc finger, nucleic acid binding protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of CNBP mRNA

NCBI chr 4:120,302,768...120,311,694
Ensembl chr 4:120,302,771...120,311,637

G

cAMP responsive element binding protein 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein; pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]

PMID:32920012 PMID:34571074

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of CYP1B1 mRNA

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

DAZ associated protein 1

increases expression

Antimony Potassium Tartrate results in increased expression of DAZAP1 mRNA

NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818

G

decapping mRNA 1A

increases expression

Antimony Potassium Tartrate results in increased expression of DCP1A mRNA

NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140

G

dehydrogenase/reductase 9

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B4

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of DNAJB4 mRNA

NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089

G

desmocollin 1

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of DSC1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSC1 mRNA]

PMID:28713220 PMID:32076005

NCBI chr18:11,499,936...11,556,801
Ensembl chr18:11,502,003...11,528,494

G

desmoglein 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:11,674,687...11,705,383
Ensembl chr18:11,674,402...11,703,443

G

dystonin

decreases expression

Antimony Potassium Tartrate results in decreased expression of DST protein

NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615

G

dual oxidase 1

multiple interactions
decreases expression

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]
Antimony Potassium Tartrate results in decreased expression of DUOX1 mRNA

NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563

G

dual oxidase maturation factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of DUOXA1 mRNA

NCBI chr 3:109,249,815...109,260,511
Ensembl chr 3:109,249,923...109,260,499

G

dual specificity phosphatase 1

increases expression

Antimony Potassium Tartrate results in increased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

dual specificity phosphatase 12

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP12 mRNA]

NCBI chr13:83,122,192...83,131,800
Ensembl chr13:83,122,193...83,131,285

G

dual specificity phosphatase 2

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [BMP6 protein results in increased expression of DUSP2 mRNA]

NCBI chr 3:114,556,325...114,558,510
Ensembl chr 3:114,556,325...114,558,499

G

early growth response 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

ets homologous factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EHF mRNA

NCBI chr 3:89,639,845...89,680,061
Ensembl chr 3:89,641,833...89,679,997

G

E74 like ETS transcription factor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ELF3 mRNA

NCBI chr13:46,690,460...46,695,394
Ensembl chr13:46,690,466...46,695,481

G

Eph receptor A1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA1 protein

NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846

G

Eph receptor A2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of EPHA2 protein

NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117

G

epoxide hydrolase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

coagulation factor V

decreases expression

Antimony Potassium Tartrate results in decreased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

fatty acid binding protein 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of FABP5 mRNA

NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773

G

farnesyl diphosphate farnesyl transferase 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

farnesyl diphosphate synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

fibroblast growth factor receptor 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FGFR3 mRNA

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

filaggrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of FLG mRNA
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

PMID:28713220 PMID:32076005

NCBI chr 2:178,884,793...178,912,986

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Antimony Potassium Tartrate results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box Q1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FOXQ1 mRNA

NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377

G

ferritin heavy chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTH1 mRNA; Antimony Potassium Tartrate results in increased expression of FTH1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTH1 mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin light chain 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of FTL mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of FTL mRNA

PMID:28713220 PMID:32076005

NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725

G

glucose-6-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of G6PD mRNA; Antimony Potassium Tartrate results in increased expression of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of GAPDH mRNA

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLC mRNA; Antimony Potassium Tartrate results in increased expression of GCLC protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLC mRNA

PMID:28713220 PMID:32076005

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of GCLM mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GCLM mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 3, mucin type

increases expression

Antimony Potassium Tartrate results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

glial fibrillary acidic protein

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gamma-glutamyltransferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GGT1 mRNA

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

growth hormone inducible transmembrane protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of GHITM mRNA

NCBI chr16:12,885,551...12,897,887
Ensembl chr16:12,885,553...12,897,879

G

galactosidase, alpha

increases expression

Antimony Potassium Tartrate results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

glutaredoxin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GLRX mRNA

NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680

G

glutathione peroxidase 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

grainyhead-like transcription factor 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of GRHL1 mRNA

NCBI chr 6:41,207,325...41,257,516
Ensembl chr 6:41,207,348...41,254,301

G

glutathione S-transferase omega 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of GSTO1 mRNA

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468

G

GTP binding protein 6 (putative)

increases expression

Antimony Potassium Tartrate results in increased expression of GTPBP6 mRNA

NCBI chr12:46,574,913...46,578,873
Ensembl chr12:46,574,435...46,578,873

G

helicase-like transcription factor

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HLTF mRNA

NCBI chr 2:102,549,724...102,609,492
Ensembl chr 2:102,549,724...102,609,327

G

high mobility group AT-hook 1

increases expression

Antimony Potassium Tartrate results in increased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

heme oxygenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of HMOX1 mRNA; Antimony Potassium Tartrate results in increased expression of HMOX1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HMOX1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HOP homeobox

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of HOPX mRNA

NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909

G

hydroxysteroid (17-beta) dehydrogenase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B2 mRNA

NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202

G

hydroxysteroid (17-beta) dehydrogenase 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 8

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HSPB8 mRNA

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

HIV-1 Tat interactive protein 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of HTATIP2 mRNA

NCBI chr 1:99,473,411...99,488,632
Ensembl chr 1:99,469,245...99,488,629

G

inhibitor of DNA binding 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of ID1 mRNA

NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419

G

immediate early response 2

increases expression

Antimony Potassium Tartrate results in increased expression of IER2 mRNA

NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211

G

interferon-related developmental regulator 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of IFRD1 mRNA

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

IKAROS family zinc finger 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IKZF2 mRNA

NCBI chr 9:71,046,038...71,191,296
Ensembl chr 9:71,042,440...71,190,867

G

interleukin 1 receptor antagonist

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IL1RN mRNA

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 4

multiple interactions

Antimony Potassium Tartrate inhibits the reaction [IL4 protein results in increased expression of DUOX1 mRNA]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

inhibitor of growth family, member 3

increases expression

Antimony Potassium Tartrate results in increased expression of ING3 mRNA

NCBI chr 4:50,477,954...50,505,168
Ensembl chr 4:50,477,962...50,503,715

G

integrin subunit beta 3 binding protein

increases expression

Antimony Potassium Tartrate results in increased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

inter-alpha trypsin inhibitor, heavy chain 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of ITIH3 mRNA

NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924

G

involucrin

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of IVL mRNA; Antimony Potassium Tartrate results in decreased expression of IVL protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of IVL mRNA

PMID:28713220 PMID:32076005

NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100

G

KLF transcription factor 5

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

increases expression

Antimony Potassium Tartrate results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kallikrein 1-related peptidase C10

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of KLK3 mRNA; Antimony Potassium Tartrate results in increased expression of KLK3 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of KLK3 mRNA]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

keratin 1

multiple interactions

2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]

NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844

G

keratin 10

decreases expression
multiple interactions

Antimony Potassium Tartrate results in decreased expression of KRT10 mRNA; Antimony Potassium Tartrate results in decreased expression of KRT10 protein
2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one promotes the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA; Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; U 0126 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]

PMID:28713220 PMID:32076005

NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701

G

keratinocyte differentiation associated protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of KRTDAP mRNA

NCBI chr 1:86,038,296...86,041,594
Ensembl chr 1:86,038,437...86,041,455

G

lipase A, lysosomal acid type

decreases expression

Antimony Potassium Tartrate results in decreased expression of LIPA mRNA

NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633

G

loricrin cornified envelope precursor protein

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of LORICRIN mRNA

NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807

G

leucine-rich repeats and immunoglobulin-like domains 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA

NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513

G

lanosterol synthase

decreases expression

Antimony Potassium Tartrate results in decreased expression of LSS mRNA

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

MAF bZIP transcription factor F

increases expression

Antimony Potassium Tartrate results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

mannosidase, alpha, class 1A, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of MAN1A2 mRNA

NCBI chr 2:187,947,484...188,096,332
Ensembl chr 2:187,951,617...188,096,332

G

monoamine oxidase A

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MAP2K1 mRNA

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK1 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of MAPK3 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased phosphorylation of MAPK3 protein

PMID:32076005 PMID:32920012 PMID:34571074

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

minichromosome maintenance complex component 2

increases expression

Antimony Potassium Tartrate results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

malic enzyme 1

increases expression

Antimony Potassium Tartrate results in increased expression of ME1 mRNA

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

decreases expression

Antimony Potassium Tartrate results in decreased expression of MGAT2 mRNA

NCBI chr 6:87,656,360...87,658,849
Ensembl chr 6:87,656,349...87,658,177

G

microsomal glutathione S-transferase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

metallothionein 1, pseudogene 3

increases expression

Antimony Potassium Tartrate results in increased expression of MT1E mRNA

NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135

G

metallothionein 2A

increases expression

Antimony Potassium Tartrate results in increased expression of MT2A mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

MYCN proto-oncogene, bHLH transcription factor

multiple interactions
decreases response to substance

[MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Antimony Potassium Tartrate
MYCN protein results in decreased susceptibility to Antimony Potassium Tartrate

NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590

G

NDRG family member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NDRG2 mRNA

NCBI chr15:24,600,981...24,609,621
Ensembl chr15:24,600,982...24,609,626

G

nuclear factor kappa B subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NFKB2 mRNA

NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213

G

NFKB inhibitor alpha

decreases expression

Antimony Potassium Tartrate results in decreased expression of NFKBIA mRNA

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NK3 homeobox 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA; Antimony Potassium Tartrate results in increased expression of NKX3-1 protein
bicalutamide inhibits the reaction [Antimony Potassium Tartrate results in increased expression of NKX3-1 mRNA]

NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441

G

nitric oxide synthase 2

multiple interactions

666-15 compound inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA; [Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of NQO1 mRNA; Antimony Potassium Tartrate results in increased expression of NQO1 protein
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of NQO1 mRNA

PMID:28713220 PMID:32076005

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

increases expression

Antimony Potassium Tartrate results in increased expression of NQO2 mRNA

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

OS9, endoplasmic reticulum lectin

decreases expression

Antimony Potassium Tartrate results in decreased expression of OS9 mRNA

NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745

G

oncostatin M

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

PBX homeobox 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PBX1 mRNA

NCBI chr13:80,278,766...80,588,563
Ensembl chr13:80,278,770...80,588,594

G

proliferating cell nuclear antigen

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

protein disulfide isomerase family A, member 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of PDIA4 mRNA

NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107

G

progastricsin

decreases expression

Antimony Potassium Tartrate results in decreased expression of PGC mRNA

NCBI chr 9:13,257,462...13,265,682
Ensembl chr 9:13,257,462...13,265,682

G

phosphogluconate dehydrogenase

increases expression

Antimony Potassium Tartrate results in increased expression of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

phosphoglucomutase 1

increases expression

Antimony Potassium Tartrate results in increased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

phosphoglucomutase 3

increases expression

Antimony Potassium Tartrate results in increased expression of PGM3 mRNA

NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022

G

phosphoinositide-3-kinase regulatory subunit 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

phosphoinositide-3-kinase regulatory subunit 2

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PIK3R2 mRNA

NCBI chr16:18,665,517...18,674,067
Ensembl chr16:18,665,457...18,674,065

G

pirin

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PIR mRNA

NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218

G

paired-like homeodomain 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of PITX1 mRNA

NCBI chr17:8,794,134...8,800,292
Ensembl chr17:8,794,134...8,800,291

G

PML nuclear body scaffold

affects localization
multiple interactions
increases degradation

Antimony Potassium Tartrate affects the localization of PML protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]
Antimony Potassium Tartrate results in increased degradation of PML protein mutant form

NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971

G

peptidylprolyl isomerase H

increases expression

Antimony Potassium Tartrate results in increased expression of PPIH mRNA

NCBI chr 5:132,906,324...132,924,341
Ensembl chr 5:132,906,328...132,924,267

G

peroxiredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of PRDX1 mRNA

NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856

G

phosphoserine phosphatase

decreases expression

Antimony Potassium Tartrate results in decreased expression of PSPH mRNA

NCBI chr12:26,882,524...26,905,084
Ensembl chr12:26,883,133...26,905,074

G

PTTG1 regulator of sister chromatid separation, securin

increases expression

Antimony Potassium Tartrate results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

retinoic acid receptor, alpha

increases degradation

Antimony Potassium Tartrate results in increased degradation of RARA protein mutant form

NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142

G

RNA binding protein, mRNA processing factor

increases expression

Antimony Potassium Tartrate results in increased expression of RBPMS mRNA

NCBI chr16:58,239,370...58,395,424
Ensembl chr16:58,239,474...58,395,426

G

replication factor C subunit 2

increases expression

Antimony Potassium Tartrate results in increased expression of RFC2 mRNA

NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557

G

ribonuclease H2, subunit A

increases expression

Antimony Potassium Tartrate results in increased expression of RNASEH2A mRNA

NCBI chr19:23,186,325...23,196,045
Ensembl chr19:23,186,383...23,196,041

G

ribonuclease/angiogenin inhibitor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RNH1 protein

NCBI chr 1:196,269,293...196,281,763
Ensembl chr 1:196,269,293...196,281,910

G

repetin

decreases expression

Antimony Potassium Tartrate results in decreased expression of RPTN mRNA

NCBI chr 2:179,061,768...179,066,056
Ensembl chr 2:179,060,017...179,065,910

G

ryanodine receptor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812

G

S100 calcium binding protein A2

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A2 mRNA

NCBI chr 2:176,077,081...176,078,325

G

S100 calcium binding protein A8

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A8 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A8 protein

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

decreases expression

Antimony Potassium Tartrate results in decreased expression of S100A9 mRNA; Antimony Potassium Tartrate results in decreased expression of S100A9 protein

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

stearoyl-CoA desaturase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SCD mRNA

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

selenophosphate synthetase 2

decreases expression

Antimony Potassium Tartrate results in decreased expression of SEPHS2 mRNA

NCBI chr 1:181,893,146...181,895,464
Ensembl chr 1:181,892,599...181,895,497

G

serpin family B member 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINB1 mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102

G

serpin family C member 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SERPINC1 mRNA

NCBI chr13:73,257,208...73,271,476
Ensembl chr13:73,257,179...73,284,293

G

serpin family E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

salt-inducible kinase 1

increases expression

Antimony Potassium Tartrate results in increased expression of SIK1 mRNA

NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991

G

solute carrier family 2 member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SLC2A3 mRNA

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

small nuclear ribonucleoprotein polypeptide A

increases expression

Antimony Potassium Tartrate results in increased expression of SNRPA mRNA

NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538

G

superoxide dismutase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

small proline-rich protein 1A

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1A mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1A protein

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR1B mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR1B protein

NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567

G

small proline-rich protein 3

decreases expression

Antimony Potassium Tartrate results in decreased expression of SPRR3 mRNA; Antimony Potassium Tartrate results in decreased expression of SPRR3 protein

NCBI chr 2:178,027,743...178,028,501
Ensembl chr 2:178,027,425...178,029,891

G

squalene epoxidase

decreases expression

Antimony Potassium Tartrate results in decreased expression of SQLE mRNA

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sequestosome 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine and arginine rich splicing factor 1

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF1 mRNA

NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336

G

serine and arginine rich splicing factor 5

decreases expression

Antimony Potassium Tartrate results in decreased expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

sulfiredoxin 1

increases expression

Antimony Potassium Tartrate results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 4

decreases expression

Antimony Potassium Tartrate results in decreased expression of ST6GALNAC4 mRNA

NCBI chr 3:15,872,230...15,885,250
Ensembl chr 3:15,872,532...15,885,243

G

signal transducer and activator of transcription 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] inhibits the reaction [OSM protein results in increased phosphorylation of STAT1 protein]; [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of STAT1 mRNA

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

sulfotransferase family 1C member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1C3 mRNA

NCBI chr 9:7,221,580...7,266,991
Ensembl chr 9:7,221,578...7,267,030

G

sulfotransferase family 1E member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT1E1 mRNA

NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275

G

sulfotransferase family 2B member 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of SULT2B1 mRNA

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295

G

small ubiquitin-like modifier 1

affects localization
multiple interactions

Antimony Potassium Tartrate affects the localization of SUMO1 protein
Antimony Potassium Tartrate promotes the reaction [SUMO1 protein binds to PML protein]

NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761

G

TAR DNA binding protein

decreases expression

Antimony Potassium Tartrate results in decreased expression of TARDBP mRNA

NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055

G

transglutaminase 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TGM1 mRNA

NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523

G

TNF alpha induced protein 3

increases expression

Antimony Potassium Tartrate results in increased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF superfamily member 10

decreases expression

Antimony Potassium Tartrate results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

transducer of ErbB-2.1

decreases expression

Antimony Potassium Tartrate results in decreased expression of TOB1 mRNA

NCBI chr10:79,163,093...79,165,131
Ensembl chr10:79,160,154...79,165,215

G

tumor protein p63

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TP63 mRNA

NCBI chr11:74,838,858...75,049,764
Ensembl chr11:74,838,859...75,049,398

G

triosephosphate isomerase 1

increases expression

Antimony Potassium Tartrate results in increased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

TSC22 domain family, member 3

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

tetraspanin 7

decreases expression

Antimony Potassium Tartrate results in decreased expression of TSPAN7 mRNA

NCBI chr X:12,208,783...12,306,092
Ensembl chr X:12,208,783...12,306,131

G

tuftelin 1

increases expression

Antimony Potassium Tartrate results in increased expression of TUFT1 mRNA

NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192

G

thioredoxin 1

multiple interactions

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

thioredoxin reductase 1

increases expression
multiple interactions

Antimony Potassium Tartrate results in increased expression of TXNRD1 mRNA
[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of TXNRD1 mRNA

PMID:17547211 PMID:28713220 PMID:32076005

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

thymidylate synthetase

increases expression

Antimony Potassium Tartrate results in increased expression of TYMS mRNA

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

ubiquitin-conjugating enzyme E2C

increases expression

Antimony Potassium Tartrate results in increased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions
increases expression

[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of UGT1A6 mRNA
Antimony Potassium Tartrate results in increased expression of UGT1A6 mRNA

PMID:28713220 PMID:32076005

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

ZW10 interacting kinetochore protein

increases expression

Antimony Potassium Tartrate results in increased expression of ZWINT mRNA

NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957

diprotium oxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

agouti related neuropeptide

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AGRP mRNA]

NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584

G

AKT serine/threonine kinase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of AKT1 mRNA

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aquaporin 1

increases transport
multiple interactions

AQP1 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP1 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP1 protein results in increased transport of Water]

PMID:7528928 PMID:8457558 PMID:10559675 PMID:11035042 PMID:11078688 More...

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 11

multiple interactions
increases transport

Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP11 protein results in increased transport of Water]

NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725

G

aquaporin 2

increases expression

Water deficiency results in increased expression of AQP2 mRNA

NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468

G

aquaporin 3 (Gill blood group)

multiple interactions
increases expression
increases transport

Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]; Mercaptoethanol inhibits the reaction [Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [Dexamethasone promotes the reaction [AQP3 protein results in increased transport of Water]]
Water deficiency results in increased expression of AQP3 mRNA; Water deficiency results in increased expression of AQP3 protein
Copper Sulfate inhibits the reaction [AQP3 protein results in increased transport of Water]; Mercuric Chloride inhibits the reaction [AQP3 protein results in increased transport of Water]

PMID:9124401 PMID:9374739 PMID:15462210 PMID:22687538

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 4

increases transport
increases response to substance
increases expression
affects transport

AQP4 protein results in increased transport of Water
AQP4 protein results in increased susceptibility to Water
Water deficiency results in increased expression of AQP4 mRNA
AQP4 protein affects the transport of Water

PMID:7528931 PMID:15462210 PMID:20815926 PMID:21251984

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

aquaporin 7

affects transport
increases transport

AQP7 protein affects the transport of Water
AQP7 protein results in increased transport of Water

PMID:9252401 PMID:18059526

NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642

G

aquaporin 8

multiple interactions
increases transport
affects transport

Copper affects the reaction [AQP8 protein affects the transport of Water]; Mercury affects the reaction [AQP8 protein affects the transport of Water]
AQP8 protein results in increased transport of Water
Mercuric Chloride inhibits the reaction [AQP8 protein results in increased transport of Water]

PMID:18059526 PMID:19840149

NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158

G

aquaporin 9

multiple interactions
increases transport
affects transport

CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; Mercuric Chloride inhibits the reaction [AQP9 protein results in increased transport of Water]; Mercury inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [AQP9 protein results in increased transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

PMID:9514918 PMID:9733774 PMID:10205677 PMID:12606488 PMID:21259319 More...

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

arginine vasopressin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of AVP protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA]

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2, apoptosis regulator

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 1

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

BCL2 interacting protein 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein; Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

CART prepropeptide

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA; [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of CASP1 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]

PMID:29335169 PMID:38705399

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased activity of CAT protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of CAT mRNA

PMID:29335169 PMID:31042592

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of CCL2 protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]

PMID:31042592 PMID:38705399

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

CF transmembrane conductance regulator

multiple interactions

1-Methyl-3-isobutylxanthine promotes the reaction [CFTR protein affects the transport of Water]; CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]; lonidamine inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [CFTR protein affects the transport of Water]; Phloretin inhibits the reaction [CFTR protein promotes the reaction [AQP9 protein affects the transport of Water]]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

cannabinoid receptor 1

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CNR1 protein

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

collagen type III alpha 1 chain

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of COL3A1 protein]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

complement C3b/C4b receptor 1 like

multiple interactions

[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in decreased expression of CR1L protein]

NCBI chr13:106,606,952...106,660,442
Ensembl chr13:106,574,858...106,660,445

G

corticotropin releasing hormone

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CRH mRNA

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

cystatin C

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in decreased expression of CYP2E1 mRNA

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

endothelin 1

affects export

EDN1 protein affects the export of Water

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

fibroblast growth factor 2

increases expression

Water results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutathione peroxidase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione-disulfide reductase

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of GSR mRNA

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

heparin-binding EGF-like growth factor

decreases expression

Water results in decreased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

hypocretin neuropeptide precursor

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA; AM 251 inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of HCRT mRNA]

NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210

G

high mobility group box 1

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

increases expression
multiple interactions

Water deficiency results in increased expression of HMOX1 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of HMOX1 mRNA

PMID:22060896 PMID:29335169

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hematopoietic prostaglandin D synthase

multiple interactions

Water affects the reaction [Isoquinolines analog binds to and results in decreased activity of HPGDS protein]

NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883

G

interleukin 10

multiple interactions

[Gum Arabic co-treated with Water deficiency co-treated with Diclofenac] results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of IL1B protein]
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]

PMID:29335169 PMID:31042592 PMID:38705399

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

metallothionein 2A

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which affects the expression of MT2 mRNA

NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784

G

NFE2 like bZIP transcription factor 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA; [Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neuropeptide Y

multiple interactions

[AM 251 co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of NPY mRNA

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

oxytocin/neurophysin I prepropeptide

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA; [Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein]

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

pro-melanin-concentrating hormone

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA; arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA]

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

proopiomelanocortin

multiple interactions

[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA; AM 251 promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA]

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

PYD and CARD domain containing

multiple interactions

[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

solute carrier family 12 member 1

multiple interactions
increases import

[Glucose results in increased activity of SLC12A1 protein] which results in increased import of Water; [Mannitol results in increased activity of SLC12A1 protein] which results in increased import of Water
SLC12A1 protein results in increased import of Water

NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899

G

solute carrier family 5 member 3

increases expression

Water deficiency results in increased expression of SLC5A3 mRNA

NCBI chr11:31,313,847...31,316,293
Ensembl chr11:31,295,476...31,318,883

G

superoxide dismutase 1

multiple interactions

[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

increases expression
multiple interactions

Water deficiency results in increased expression of SOD2 protein
[[Particulate Matter co-treated with Water] results in increased abundance of Metals] which results in increased expression of SOD2 mRNA

PMID:22718889 PMID:29335169

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sequestosome 1

multiple interactions

[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

tachykinin, precursor 1

multiple interactions

TAC1 protein alternative form inhibits the reaction [Cholera Toxin results in increased secretion of Water]; TAC1 protein inhibits the reaction [Cholera Toxin results in increased secretion of Water]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

tumor necrosis factor

multiple interactions

[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein; Gum Arabic inhibits the reaction [[Water deficiency co-treated with Diclofenac] results in increased expression of TNF protein]
[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]

PMID:31042592 PMID:38705399

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

enalaprilat dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of ACE protein]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

adrenoceptor beta 1

affects expression

Enalaprilat affects the expression of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

affects expression

Enalaprilat affects the expression of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

decreases expression
multiple interactions

Enalaprilat results in decreased expression of AGT protein modified form
Enalaprilat inhibits the reaction [Glucose results in increased expression of AGT protein]

PMID:16452552 PMID:21795644

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

angiotensin II receptor, type 1a

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in increased expression of AGTR1 protein]

NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946

G

BCL2, apoptosis regulator

increases expression

Enalaprilat results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bradykinin receptor B1

multiple interactions
increases activity

bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [Enalaprilat results in increased activity of BDKRB1 protein]; Zinc affects the reaction [Enalaprilat results in increased activity of BDKRB1 protein]

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

endothelin 1

decreases secretion

Enalaprilat results in decreased secretion of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

fibronectin 1

decreases expression
multiple interactions

Enalaprilat results in decreased expression of FN1 mRNA; Enalaprilat results in decreased expression of FN1 protein
Enalaprilat inhibits the reaction [Glucose results in increased expression of FN1 mRNA]

PMID:14520012 PMID:21795644

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glutamate dehydrogenase 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in decreased expression of GLUD2 mRNA]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamate metabotropic receptor 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of GRM1 mRNA]

NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170

G

high mobility group box 1

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 mRNA]; Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

insulin 2

multiple interactions

Enalaprilat inhibits the reaction [Glucose results in decreased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

peroxisome proliferator-activated receptor delta

multiple interactions

[Enalaprilat co-treated with Daunorubicin] results in increased expression of PPARD mRNA

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

renin

increases expression

Enalaprilat results in increased expression of REN mRNA

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

serpin family E member 1

decreases expression

Enalaprilat results in decreased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 22 member 8

multiple interactions
increases uptake

verlukast inhibits the reaction [SLC22A8 protein results in increased uptake of Enalaprilat]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

G

transforming growth factor, beta 1

decreases expression

Enalaprilat results in decreased expression of TGFB1 mRNA; Enalaprilat results in decreased expression of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions

Enalaprilat inhibits the reaction [Dexamethasone results in increased expression of TLR4 mRNA]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

decreases expression

Enalaprilat results in decreased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

gadodiamide hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

decreases expression

gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

gadodiamide results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

aldehyde dehydrogenase 1 family, member A1

increases expression

gadodiamide results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

ankyrin repeat domain 22

increases expression

gadodiamide results in increased expression of ANKRD22 mRNA

NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381

G

ATM serine/threonine kinase

increases expression

gadodiamide results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase phospholipid transporting 8B1

increases expression

gadodiamide results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

C-C motif chemokine ligand 2

increases expression
increases secretion

gadodiamide results in increased expression of CCL2 mRNA
gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein
gadodiamide results in increased secretion of CCL2 protein

PMID:20938346 PMID:20959327

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

increases expression

gadodiamide results in increased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

increases expression

gadodiamide results in increased expression of CCL7 protein

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

centrosomal protein 15

increases expression

gadodiamide results in increased expression of CEP15 mRNA

NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838

G

C-X-C motif chemokine ligand 10

increases expression
increases secretion

gadodiamide results in increased expression of CXCL10 mRNA
gadodiamide results in increased expression of CXCL10 protein
gadodiamide results in increased secretion of CXCL10 protein

PMID:20938346 PMID:20959327

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases secretion
increases expression

gadodiamide results in increased secretion of CXCL11 protein
gadodiamide results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

C-X-C motif chemokine ligand 12

increases expression

gadodiamide results in increased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 9

increases expression

gadodiamide results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

fatty acid binding protein 4

decreases expression

gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

indoleamine 2,3-dioxygenase 1

increases expression

gadodiamide results in increased expression of IDO1 mRNA

NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730

G

interferon-induced protein 44-like

increases expression

gadodiamide results in increased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon-induced protein with tetratricopeptide repeats 3

increases expression

gadodiamide results in increased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307

G

interferon gamma

increases expression

gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 13

increases expression

gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 alpha

increases expression

gadodiamide results in increased expression of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 4

increases expression
affects expression

gadodiamide results in increased expression of IL4 protein
gadodiamide affects the expression of IL4 mRNA

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 4 induced 1

increases expression

gadodiamide results in increased expression of IL4I1 mRNA

NCBI chr 1:95,299,457...95,324,564
Ensembl chr 1:95,295,601...95,324,562

G

interleukin 6

affects expression
increases expression

gadodiamide affects the expression of IL6 protein
gadodiamide results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KIT ligand

increases expression

gadodiamide results in increased expression of KITLG protein

NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]
gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

nitric oxide synthase 2

increases expression

gadodiamide results in increased expression of NOS2 protein

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurexophilin and PC-esterase domain family, member 3

increases expression

gadodiamide results in increased expression of NXPE3 mRNA

NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694

G

peroxisome proliferator-activated receptor gamma

decreases expression

gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

RELA proto-oncogene, NF-kB subunit

increases localization

gadodiamide results in increased localization of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ras homolog family member Q

increases expression

gadodiamide results in increased expression of RHOQ mRNA

NCBI chr 6:7,613,632...7,652,047

G

Ras-like without CAAX 1

increases expression

gadodiamide results in increased expression of RIT1 mRNA

NCBI chr 2:174,180,742...174,195,455
Ensembl chr 2:174,180,848...174,195,455

G

ring finger protein 125

increases expression

gadodiamide results in increased expression of RNF125 mRNA

NCBI chr18:12,254,066...12,275,719
Ensembl chr18:12,253,852...12,275,983

G

radical S-adenosyl methionine domain containing 2

increases expression

gadodiamide results in increased expression of RSAD2 mRNA

NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699

G

solute carrier family 39 member 10

increases expression

gadodiamide results in increased expression of SLC39A10 mRNA

NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:54,876,141...54,960,325

G

sialophorin

increases expression

gadodiamide results in increased expression of SPN mRNA

NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628

G

secreted phosphoprotein 1

increases expression

gadodiamide results in increased expression of SPP1 protein

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

transforming growth factor, beta 1

increases expression

gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein

PMID:19404939 PMID:20938346

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TIMP metallopeptidase inhibitor 1

increases expression
multiple interactions

gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein]

PMID:19561517 PMID:20938346

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

ubiquitin D

increases expression

gadodiamide results in increased expression of UBD mRNA

NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639
Ensembl chr20:1,385,864...1,408,639

G

vascular endothelial growth factor A

increases expression

gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein

PMID:19404939 PMID:20938346

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

WD repeat domain 5

increases expression

gadodiamide results in increased expression of WDR5 mRNA

NCBI chr 3:10,836,964...10,856,682
Ensembl chr 3:10,837,025...10,856,671

G

X-linked inhibitor of apoptosis

increases expression

gadodiamide results in increased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

zinc finger protein 652

increases expression

gadodiamide results in increased expression of ZNF652 mRNA

NCBI chr10:80,626,555...80,706,397
Ensembl chr10:80,649,400...80,698,674

lisinopril dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin I converting enzyme

decreases activity

Lisinopril analog results in decreased activity of ACE protein

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

angiotensin converting enzyme 2

increases expression
multiple interactions
increases activity

Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]
Lisinopril results in increased activity of ACE2 protein

PMID:15897343 PMID:16221218 PMID:27649628

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acetylcholinesterase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]

PMID:23060470 PMID:31710167

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

angiotensinogen

decreases expression
increases expression
affects response to substance
increases secretion
decreases secretion
multiple interactions
affects metabolic processing

Lisinopril results in decreased expression of AGT protein
Lisinopril results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in increased secretion of AGT protein alternative form
Lisinopril results in decreased secretion of AGT protein
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
Lisinopril affects the metabolism of AGT protein
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]

PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

BCL2, apoptosis regulator

decreases expression

Lisinopril results in decreased expression of BCL2

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

CD2-associated protein

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein]

NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199

G

endothelin 1

decreases secretion

Lisinopril results in decreased secretion of EDN1 protein

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

growth hormone 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

hepatitis A virus cellular receptor 1

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein]

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

heparanase

multiple interactions

[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

insulin-like growth factor binding protein 1

increases expression

Lisinopril results in increased expression of IGFBP1 protein

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

matrix metallopeptidase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myeloperoxidase

multiple interactions

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nitric oxide synthase 2

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NPHS2 stomatin family member, podocin

multiple interactions

Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein]

NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313

G

natriuretic peptide A

decreases expression

Lisinopril results in decreased expression of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

renin

increases expression
multiple interactions

Lisinopril results in increased expression of REN protein
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA
Lisinopril results in increased expression of REN mRNA

PMID:2550029 PMID:8915971 PMID:16221218

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

RT1 class Ib, locus M3, gene 1

affects expression

Lisinopril affects the expression of HLA-G mRNA

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

sperm microtubule inner protein 11

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein]

PMID:16636307 PMID:19293598

NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

vascular endothelial growth factor A

multiple interactions

Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

magnesium dihydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:18604214 PMID:22075093

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

cholinergic receptor nicotinic alpha 4 subunit

multiple interactions

Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957

G

cholinergic receptor nicotinic beta 2 subunit

multiple interactions

Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]]

NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619

G

C-X-C motif chemokine ligand 10

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

interleukin 1 beta

multiple interactions

[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein]
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

PMID:17404311 PMID:18604214 PMID:22075093

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

multiple interactions

IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 2

multiple interactions

[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

NLR family, pyrin domain containing 3

multiple interactions

NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

PYD and CARD domain containing

multiple interactions

PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

toll-like receptor 4

multiple interactions

TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

mosapride citrate dihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

anoctamin 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 mRNA]; mosapride inhibits the reaction [Loperamide results in decreased expression of ANO1 protein]

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

5-hydroxytryptamine receptor 4

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of HTR4 mRNA]

NCBI chr18:55,765,981...55,949,921
Ensembl chr18:55,766,725...55,949,321

G

myosin light chain kinase

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of MYLK mRNA]

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

nitric oxide synthase 1

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of NOS1 protein]

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

ryanodine receptor 3

multiple interactions

mosapride inhibits the reaction [Loperamide results in decreased expression of RYR3 mRNA]

NCBI chr 3:99,431,755...99,979,125
Ensembl chr 3:99,432,505...99,704,961

G

solute carrier family 22 member 2

multiple interactions

mosapride inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

potassium citrate monohydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

neurofilament heavy chain

affects expression

Potassium Citrate affects the expression of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

potassium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cofilin 1

increases expression

potassium hydroxide results in increased expression of CFL1 mRNA; potassium hydroxide results in increased expression of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

heat shock protein family B (small) member 1

multiple interactions
increases expression

potassium hydroxide results in decreased expression of and affects the localization of HSPB1 protein
potassium hydroxide results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

interleukin 1 alpha

multiple interactions

potassium hydroxide results in increased expression of and results in increased secretion of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

superoxide dismutase 1

increases expression
decreases expression

potassium hydroxide results in increased expression of SOD1 mRNA
potassium hydroxide results in decreased expression of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

royal jelly

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCL2 associated X, apoptosis regulator

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA]
royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein]

PMID:30896085 PMID:34227456

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

caspase 3

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA]
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein]

PMID:30896085 PMID:34227456

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 6

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein]

NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502

G

caspase 9

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein]
royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein]

PMID:20369241 PMID:30896085 PMID:34227456

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

multiple interactions

royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA]

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

E2F transcription factor 1

multiple interactions

royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

estrogen receptor 1

multiple interactions
affects binding
increases activity

Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein]
royal jelly results in increased activity of ESR1 protein

PMID:15946813 PMID:17287592

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions
affects binding

Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein]

PMID:15946813 PMID:17287592

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

glycogen synthase kinase 3 beta

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

insulin 1

multiple interactions

royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
decreases expression

royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA]
royal jelly results in decreased expression of MYC mRNA
royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA]

PMID:27496854 PMID:35099105

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

NFE2 like bZIP transcription factor 2

multiple interactions

royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

proliferating cell nuclear antigen

multiple interactions

royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein]

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

trefoil factor 1

increases expression

royal jelly results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tumor protein p53

multiple interactions

royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

vascular endothelial growth factor A

increases expression

royal jelly results in increased expression of VEGFA mRNA

PMID:15946813 PMID:17287592

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

sodium acetate trihydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 1

increases expression

Sodium Acetate results in increased expression of ACOX1 mRNA

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase short-chain family member 1

increases expression

Sodium Acetate results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

increases expression

Sodium Acetate results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

adenosine deaminase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of ADA protein]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

apolipoprotein B

multiple interactions

[Sodium Acetate co-treated with acetic anhydride] results in increased acetylation of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

caspase 3

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in increased cleavage of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

catalase

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1A1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

Sodium Acetate promotes the reaction [biochanin A results in increased expression of CYP1B1 mRNA]; Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

gamma-glutamyltransferase 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of GGT1 protein]

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

interferon gamma

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 protein]

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 6

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased expression of INS1 protein]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

karyopherin subunit beta 1

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]

NCBI chr10:82,145,662...82,174,437
Ensembl chr10:82,145,420...82,174,605

G

MYD88, innate immune signal transduction adaptor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of MYD88 mRNA]

NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415

G

N-acetyltransferase 2

increases expression

Sodium Acetate results in increased expression of NAT2 mRNA

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

nuclear factor of activated T-cells 2

multiple interactions

Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] affects the localization of NFATC2 protein]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] promotes the reaction [NFATC2 protein binds to KPNB1 protein]]; Sodium Acetate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of NFATC2 protein]

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

NFKB inhibitor alpha

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in decreased expression of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

phosphoenolpyruvate carboxykinase 1

increases expression

Sodium Acetate results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of and results in increased phosphorylation of RELA protein]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of RELA mRNA]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

superoxide dismutase 2

multiple interactions

Sodium Acetate inhibits the reaction [Cisplatin results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transforming growth factor, beta 1

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TGFB1 mRNA]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 2

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR2 protein]

NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630

G

toll-like receptor 4

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 mRNA]; [Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

[Sodium Acetate co-treated with Butyric Acid co-treated with sodium propionate] inhibits the reaction [Fluorides results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

Sodium Acetate promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of UGT1A1 mRNA]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

xanthine dehydrogenase

multiple interactions

Sodium Acetate inhibits the reaction [Nicotine results in increased activity of XDH protein]

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

sodium hydroxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

caspase 3

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of CASP3 mRNA
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of CASP3 mRNA]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

collagen type I alpha 2 chain

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of COL1A2 protein
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of COL1A2 protein]

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type III alpha 1 chain

multiple interactions
increases expression

lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of COL3A1 protein]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

epidermal growth factor receptor

affects response to substance

EGFR SNP affects the susceptibility to Sodium Hydroxide

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

ezrin

increases expression

Sodium Hydroxide results in increased expression of EZR mRNA

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

fibronectin 1

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of FN1 protein
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

immediate early response 3

affects response to substance

IER3 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interleukin 1 beta

increases expression

Sodium Hydroxide results in increased expression of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 22

affects response to substance

IL22 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of JUN mRNA
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of JUN mRNA]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium two pore domain channel subfamily K member 3

increases activity
decreases response to substance

Sodium Hydroxide results in increased activity of KCNK3 protein
KCNK3 protein mutant form results in decreased susceptibility to Sodium Hydroxide

NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153

G

matrix metallopeptidase 9

increases expression
multiple interactions

Sodium Hydroxide results in increased expression of MMP9 mRNA
lycium barbarum polysaccharide inhibits the reaction [Sodium Hydroxide results in increased expression of MMP9 mRNA]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

plasminogen activator, urokinase

affects response to substance

PLAU SNP affects the susceptibility to Sodium Hydroxide

NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775

G

RT1 class Ib, locus M3, gene 1

affects response to substance

HLA-G SNP affects the susceptibility to Sodium Hydroxide

NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117

G

tripartite motif-containing 10

affects response to substance

TRIM10 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr20:1,689,554...1,698,948
Ensembl chr20:1,689,562...1,698,252

G

tripartite motif-containing 31

affects response to substance

TRIM31 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr20:1,653,165...1,666,494
Ensembl chr20:1,653,165...1,666,494

G

tripartite motif-containing 40

affects response to substance

TRIM40 SNP affects the susceptibility to Sodium Hydroxide

NCBI chr20:1,676,114...1,685,906
Ensembl chr20:1,676,270...1,685,214

sodium thiosulfate pentahydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 3

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

myeloperoxidase

multiple interactions

sodium thiosulfate inhibits the reaction [Isoproterenol results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

tacrolimus hydrate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Tacrolimus results in increased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily A member 1

multiple interactions
increases expression

[Sirolimus co-treated with Tacrolimus] results in increased expression of ABCA1 protein
Tacrolimus results in increased expression of ABCA1 mRNA

PMID:17016853 PMID:21865292

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases activity

Tacrolimus results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects export
decreases activity
multiple interactions
increases response to substance
increases export
affects response to substance

ABCB1 protein affects the export of Tacrolimus
Tacrolimus results in decreased activity of ABCB1 protein
[Tacrolimus binds to ABCB1 protein] inhibits the reaction [azidoprazosin binds to ABCB1 protein]; [Tacrolimus results in decreased activity of ABCB1 protein] which results in decreased export of Dexamethasone; Verapamil affects the reaction [ABCB1 protein results in increased export of Tacrolimus]
ABCB1 gene SNP results in increased susceptibility to Tacrolimus
ABCB1 protein affects the susceptibility to Tacrolimus

PMID:1381629 PMID:11920757 PMID:12352921 PMID:15919446 PMID:15964336 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

acetyl-Coenzyme A acyltransferase 1B

decreases expression

Tacrolimus results in decreased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acyl-CoA dehydrogenase, long chain

decreases expression

Tacrolimus results in decreased expression of ACADL mRNA

NCBI chr 9:68,333,981...68,372,149
Ensembl chr 9:68,333,980...68,372,220

G

angiotensin converting enzyme 2

decreases expression

Tacrolimus results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acid phosphatase 5, tartrate resistant

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

actin alpha 2, smooth muscle

increases expression

Tacrolimus results in increased expression of ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

activin A receptor type 1B

multiple interactions

[Tacrolimus inhibits the reaction [FKBP1A protein binds to ACVR1B protein]] which results in decreased ubiquitination of ACVR1B protein; Tacrolimus inhibits the reaction [FKBP1A protein binds to and results in decreased activity of ACVR1B protein]; Tacrolimus inhibits the reaction [FKBP1A protein promotes the reaction [SMURF1 protein binds to SMAD7 protein binds to ACVR1B protein]]

NCBI chr 7:132,286,266...132,329,679
Ensembl chr 7:132,286,275...132,329,673

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

Tacrolimus results in increased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

increases expression

Tacrolimus results in increased expression of ADAMTS2 mRNA

NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821

G

adenylate cyclase 9

multiple interactions

Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]]

NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066

G

adrenoceptor alpha 1D

increases expression

Tacrolimus results in increased expression of ADRA1D mRNA

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

allograft inflammatory factor 1

increases expression

Tacrolimus results in increased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

Tacrolimus results in decreased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 2 family member

decreases expression

Tacrolimus results in decreased expression of ALDH2 mRNA

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 9 family, member A1

decreases expression

Tacrolimus results in decreased expression of ALDH9A1 mRNA

NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568

G

ALG3, alpha-1,3- mannosyltransferase

decreases expression

Tacrolimus results in decreased expression of ALG3 mRNA

NCBI chr11:80,300,487...80,306,014
Ensembl chr11:80,300,498...80,307,912

G

angiopoietin-like 6

increases expression

Tacrolimus results in increased expression of ANGPTL6 mRNA

NCBI chr 8:19,413,617...19,419,925
Ensembl chr 8:19,413,619...19,419,925

G

ankyrin repeat domain 1

increases expression

Tacrolimus results in increased expression of ANKRD1 mRNA

NCBI chr 1:233,815,851...233,834,891
Ensembl chr 1:233,815,851...233,834,919

G

ankyrin repeat domain 34A

decreases expression

Tacrolimus results in decreased expression of ANKRD34A mRNA

NCBI chr 2:184,129,830...184,135,075
Ensembl chr 2:184,129,238...184,135,116

G

alanyl aminopeptidase, membrane

increases secretion

Tacrolimus results in increased secretion of ANPEP protein

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

annexin A1

increases expression

Tacrolimus results in increased expression of ANXA1

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

amine oxidase, copper containing 1

increases expression

Tacrolimus results in increased expression of AOC1 mRNA

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

amphiregulin

increases expression

Tacrolimus results in increased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

ADP-ribosylation factor related protein 1

increases expression

Tacrolimus results in increased expression of ARFRP1 mRNA

NCBI chr 3:168,466,351...168,473,960
Ensembl chr 3:168,466,496...168,473,914

G

Rho GTPase activating protein 45

increases expression

Tacrolimus results in increased expression of ARHGAP45 mRNA

NCBI chr 7:9,674,873...9,690,286
Ensembl chr 7:9,674,897...9,690,268

G

Rho guanine nucleotide exchange factor 11

increases expression

Tacrolimus results in increased expression of ARHGEF11 mRNA

NCBI chr 2:173,074,383...173,195,962
Ensembl chr 2:173,074,368...173,196,010

G

actin related protein 2/3 complex, subunit 5

increases expression

Tacrolimus results in increased expression of ARPC5 mRNA

NCBI chr13:64,904,504...64,913,413
Ensembl chr13:64,887,136...64,913,410

G

ARV1 homolog, fatty acid homeostasis modulator

increases expression

Tacrolimus results in increased expression of ARV1 mRNA

NCBI chr19:52,692,337...52,704,156
Ensembl chr19:52,692,337...52,704,156

G

ASXL transcriptional regulator 3

decreases expression

Tacrolimus results in decreased expression of ASXL3 mRNA

NCBI chr18:13,593,529...13,766,324
Ensembl chr18:13,593,985...13,762,427

G

activating transcription factor 3

increases expression

Tacrolimus results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

increases expression

Tacrolimus results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Tacrolimus results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATPase Na+/K+ transporting subunit beta 1

decreases expression

Tacrolimus results in decreased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATPase Na+/K+ transporting subunit beta 3

decreases expression

Tacrolimus results in decreased expression of ATP1B3 mRNA

NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Tacrolimus results in increased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

beta-2 microglobulin

increases expression

Tacrolimus results in increased expression of B2M mRNA

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

BCL2-associated agonist of cell death

multiple interactions

Tacrolimus inhibits the reaction [Ammonium Chloride results in decreased phosphorylation of BAD protein]
Tacrolimus inhibits the reaction [Rotenone results in decreased phosphorylation of BAD protein]

PMID:15036616 PMID:15280438

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

basic leucine zipper ATF-like transcription factor 3

increases expression

Tacrolimus results in increased expression of BATF3 mRNA

NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of BAX protein]
Tacrolimus results in increased expression of BAX protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BAX protein

PMID:10205001 PMID:15571979 PMID:27606422 PMID:35033536

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in decreased expression of BCL2 protein]
Tacrolimus results in decreased expression of BCL2 protein
[Tacrolimus co-treated with 3-nitropropionic acid] affects the localization of BCL2 protein
Tacrolimus results in increased expression of BCL2 protein

PMID:10205001 PMID:15571979 PMID:27606422

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

Tacrolimus inhibits the reaction [Superantigens results in increased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

BCL3, transcription coactivator

increases expression

Tacrolimus results in increased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

brain-derived neurotrophic factor

multiple interactions

Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]; Tacrolimus promotes the reaction [U 0126 inhibits the reaction [decamethrin results in increased expression of BDNF exon]]; U 0126 promotes the reaction [Tacrolimus inhibits the reaction [decamethrin results in increased expression of BDNF exon]]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

baculoviral IAP repeat-containing 3

increases expression

Tacrolimus results in increased expression of BIRC3 mRNA

NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802

G

baculoviral IAP repeat-containing 5

decreases expression

Tacrolimus results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 7

multiple interactions
decreases expression

Ramipril inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]; valsartan inhibits the reaction [Tacrolimus results in decreased expression of BMP7 protein]

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

BTG anti-proliferation factor 2

increases expression

Tacrolimus results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

butyrophilin-like 9

decreases expression

Tacrolimus results in decreased expression of BTNL9 mRNA

NCBI chr10:33,466,059...33,489,229
Ensembl chr10:33,470,536...33,489,025

G

complement C1q A chain

increases expression

Tacrolimus results in increased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

increases expression

Tacrolimus results in increased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

complement C1q C chain

increases expression

Tacrolimus results in increased expression of C1QC mRNA

NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017

G

complement C2

increases expression

Tacrolimus results in increased expression of C2 mRNA

NCBI chr20:3,951,474...3,970,376
Ensembl chr20:3,951,474...3,976,505

G

complement C3

increases expression

Tacrolimus results in increased expression of C3 mRNA

PMID:21865292 PMID:29362864

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C4B

increases expression

Tacrolimus results in increased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

calbindin 1

decreases expression

Tacrolimus results in decreased expression of CALB1 mRNA; Tacrolimus results in decreased expression of CALB1 protein

PMID:14978156 PMID:21865292

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431

G

calcitonin receptor

multiple interactions

Tacrolimus inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]

NCBI chr 4:31,661,270...31,736,392
Ensembl chr 4:31,661,273...31,736,392

G

calreticulin

increases expression

Tacrolimus results in increased expression of CALR mRNA

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase ID

increases expression

Tacrolimus results in increased expression of CAMK1D mRNA

NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556

G

capping actin protein, gelsolin like

increases expression

Tacrolimus results in increased expression of CAPG mRNA

NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856

G

caspase 3

multiple interactions
increases cleavage
increases activity

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]
Tacrolimus results in increased cleavage of CASP3 protein
Tacrolimus results in increased activity of CASP3 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; NGF protein inhibits the reaction [Tacrolimus results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [3-nitropropionic acid results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [[Lithium co-treated with Pilocarpine] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [Oxygen deficiency results in increased activity of CASP3 protein]
Tacrolimus inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased activity of CASP3 protein]; Tacrolimus inhibits the reaction [S-Nitrosoglutathione results in increased activity of CASP3 protein]

PMID:10205001 PMID:12642403 PMID:12871656 PMID:12892836 PMID:15207740 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
Tacrolimus results in increased expression of CASP8 protein

PMID:15548389 PMID:27606422

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions
increases expression

Tacrolimus inhibits the reaction [FAS protein results in increased activity of CASP9 protein]
Tacrolimus results in increased expression of CASP9 protein

PMID:15548389 PMID:27606422

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

increases expression
decreases response to substance

Tacrolimus results in increased expression of CAT protein
CAT protein results in decreased susceptibility to Tacrolimus

PMID:14675044 PMID:18766458

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

Cbl proto-oncogene like 1

increases expression

Tacrolimus results in increased expression of CBLL1 mRNA

NCBI chr 6:48,071,190...48,086,174
Ensembl chr 6:48,071,190...48,086,444

G

coiled-coil domain containing 88B

increases expression

Tacrolimus results in increased expression of CCDC88B mRNA

NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970

G

C-C motif chemokine ligand 11

decreases expression

Tacrolimus results in decreased expression of CCL11 mRNA

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 17

increases expression

Tacrolimus results in increased expression of CCL17 mRNA

NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

pyrrolidine dithiocarbamic acid inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]
Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL2 protein]
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; 7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]

PMID:12472797 PMID:23958496 PMID:29362864 PMID:36416909

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 20

increases expression

Tacrolimus results in increased expression of CCL20 mRNA

NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629

G

C-C motif chemokine ligand 3

multiple interactions

Tacrolimus inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CCL5 mRNA
Tacrolimus results in increased expression of CCL5 mRNA
7-oxozeanol inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; parthenolide inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; salubrinal inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]; sulforaphane inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA]

PMID:15948978 PMID:23958496 PMID:25270620

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-C motif chemokine ligand 7

increases expression

Tacrolimus results in increased expression of CCL7 mRNA

PMID:23958496 PMID:29362864

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

C-C motif chemokine ligand 9

increases expression

Tacrolimus results in increased expression of CCL6 mRNA

PMID:21865292 PMID:29362864

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cellular communication network factor 2

multiple interactions

Tacrolimus inhibits the reaction [Paraquat results in increased expression of CCN2 mRNA]; Tacrolimus inhibits the reaction [Paraquat results in increased secretion of CCN2 protein]

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

increases expression

Tacrolimus results in increased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B2

decreases expression
increases expression

Tacrolimus results in decreased expression of CCNB2 mRNA
Tacrolimus results in increased expression of CCNB2 mRNA

PMID:16574167 PMID:29362864

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

C-C motif chemokine receptor 2

increases expression

Tacrolimus results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 3

decreases expression

Tacrolimus results in decreased expression of CCR3 mRNA

NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990

G

C-C motif chemokine receptor like 2

increases expression

Tacrolimus results in increased expression of CCRL2 mRNA

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664

G

Cd2 molecule

multiple interactions

Tacrolimus inhibits the reaction [CD2 protein results in increased expression of IL2 protein]

NCBI chr 2:188,710,895...188,724,044
Ensembl chr 2:188,710,900...188,724,026

G

CD44 molecule

increases expression

Tacrolimus results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

Cd68 molecule

increases expression

Tacrolimus results in increased expression of CD68 mRNA

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

CD74 molecule

increases expression

Tacrolimus results in increased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

Cd80 molecule

decreases expression

Tacrolimus results in decreased expression of CD80 protein

NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030

G

CD83 molecule

increases expression

Tacrolimus results in increased expression of CD83 mRNA

NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083

G

CD86 molecule

decreases expression

Tacrolimus results in decreased expression of CD86 protein

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cell division cycle associated 3

increases expression

Tacrolimus results in increased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 5

increases expression

Tacrolimus results in increased expression of CDCA5 mRNA

NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 8

increases expression

Tacrolimus results in increased expression of CDCA8 mRNA

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 1

decreases expression

Tacrolimus results in decreased expression of CDH1 protein

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 11

increases expression

Tacrolimus results in increased expression of CDH11 mRNA

NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272

G

cadherin 16

decreases expression

Tacrolimus results in decreased expression of CDH16 mRNA

NCBI chr19:360,824...371,008
Ensembl chr19:360,824...371,007

G

cyclin-dependent kinase inhibitor 1B

increases expression

Tacrolimus results in increased expression of CDKN1B mRNA

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

CCAAT/enhancer binding protein alpha

increases expression

Tacrolimus results in increased expression of CEBPA mRNA

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

centromere protein W

increases expression

Tacrolimus results in increased expression of CENPW mRNA

NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464

G

complement factor I

increases expression

Tacrolimus results in increased expression of CFI mRNA

NCBI chr 2:218,389,079...218,430,565
Ensembl chr 2:218,387,990...218,430,561

G

cytoskeleton associated protein 2

increases expression

Tacrolimus results in increased expression of CKAP2 mRNA

NCBI chr16:69,839,668...69,864,852
Ensembl chr16:69,839,630...69,864,913

G

cytoskeleton-associated protein 4

increases expression

Tacrolimus results in increased expression of CKAP4 mRNA

NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914

G

claudin 1

decreases expression

Tacrolimus results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 4

increases expression

Tacrolimus results in increased expression of CLDN4 mRNA

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

claudin 7

increases expression

Tacrolimus results in increased expression of CLDN7 mRNA

NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171

G

C-type lectin domain containing 7A

increases expression

Tacrolimus results in increased expression of CLEC7A mRNA

NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897

G

CDC-like kinase 3

increases expression

Tacrolimus results in increased expression of CLK3 mRNA

NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181

G

clusterin

increases expression

Tacrolimus results in increased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

cochlin

increases expression

Tacrolimus results in increased expression of COCH mRNA

NCBI chr 6:69,031,139...69,045,124
Ensembl chr 6:69,031,167...69,045,109

G

collagen type I alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

increases expression

Tacrolimus results in increased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type III alpha 1 chain

increases expression

Tacrolimus results in increased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

COP9 signalosome subunit 8

increases expression

Tacrolimus results in increased expression of COPS8 mRNA

NCBI chr 9:91,207,427...91,217,258
Ensembl chr 9:91,207,395...91,217,258

G

ceruloplasmin

increases expression

Tacrolimus results in increased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element binding protein 3-like 3

decreases expression

Tacrolimus results in decreased expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

cysteine-rich with EGF-like domains 2

increases expression

Tacrolimus results in increased expression of CRELD2 mRNA

NCBI chr 7:119,909,626...119,916,556
Ensembl chr 7:119,909,633...119,916,543

G

colony stimulating factor 1

increases expression

Tacrolimus results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

decreases expression
increases expression
multiple interactions

Tacrolimus results in decreased expression of CSF2 protein
Tacrolimus results in increased expression of CSF2 mRNA
Sirolimus inhibits the reaction [Tacrolimus inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of CSF2 protein]]; Tacrolimus inhibits the reaction [[Calcimycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CSF2 protein]

PMID:1376361 PMID:11407316 PMID:23958496

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 2 receptor subunit beta

increases expression

Tacrolimus results in increased expression of CSF2RB2 mRNA

NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157

G

cathepsin L

multiple interactions
increases expression

Tacrolimus inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CTSL protein]
Tacrolimus results in increased expression of CTSL mRNA

PMID:18172886 PMID:21865292 PMID:25270620

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

C-X-C motif chemokine ligand 10

increases expression

Tacrolimus results in increased expression of CXCL10 mRNA

PMID:21865292 PMID:23958496 PMID:25270620

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases expression

Tacrolimus results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

cytochrome b-245 alpha chain

multiple interactions
increases expression

Ramipril inhibits the reaction [Tacrolimus results in increased expression of CYBA mRNA]

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome P450, family 27, subfamily b, polypeptide 1

increases expression

Tacrolimus results in increased expression of CYP27B1 mRNA

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

CYP2C19 affects the reaction [Lansoprazole affects the susceptibility to Tacrolimus]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP2C19 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP2C19 gene mutant form affects the susceptibility to [Lansoprazole co-treated with Tacrolimus]

PMID:15010519 PMID:15285851 PMID:17377957

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
affects metabolic processing
decreases methylation
multiple interactions

CYP3A4 protein results in increased metabolism of Tacrolimus
CYP3A4 protein affects the metabolism of Tacrolimus
CYP3A4 protein results in decreased methylation of Tacrolimus
Metronidazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Tacrolimus]

PMID:15010519 PMID:15855244 PMID:15919446 PMID:15951320 PMID:15964336

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
decreases methylation
affects metabolic processing
affects response to substance

CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Lansoprazole]; CYP3A5 affects the susceptibility to [Tacrolimus co-treated with Rabeprazole]; CYP3A5 gene polymorphism affects the reaction [Ketoconazole results in decreased metabolism of Tacrolimus]
CYP3A5 protein results in decreased methylation of Tacrolimus
CYP3A5 gene polymorphism affects the metabolism of Tacrolimus; CYP3A5 gene SNP affects the metabolism of Tacrolimus; CYP3A5 protein affects the metabolism of Tacrolimus; CYP3A5 protein polymorphism affects the metabolism of Tacrolimus
CYP3A5 gene affects the susceptibility to Tacrolimus; CYP3A5 polymorphism affects the susceptibility to Tacrolimus

PMID:15502717 PMID:15723604 PMID:15729180 PMID:15808586 PMID:15919447 More...

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

decorin

increases expression

Tacrolimus results in increased expression of DCN mRNA

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

salubrinal promotes the reaction [Tacrolimus results in increased expression of DDIT3 protein]
Tacrolimus results in increased expression of DDIT3 mRNA

PMID:23958496 PMID:25270620

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DNA-damage-inducible transcript 4-like

decreases expression

Tacrolimus results in decreased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

24-dehydrocholesterol reductase

decreases expression

Tacrolimus results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

DnaJ heat shock protein family (Hsp40) member C30

decreases expression

Tacrolimus results in decreased expression of DNAJC30 mRNA

NCBI chr12:21,628,319...21,629,398
Ensembl chr12:21,626,450...21,629,408

G

dynamin 1-like

multiple interactions

PINK1 protein affects the reaction [Tacrolimus results in increased phosphorylation of DNM1L protein]
Tacrolimus inhibits the reaction [ferric ammonium citrate results in decreased phosphorylation of DNM1L protein]

PMID:19492085 PMID:26318285

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

double C2 domain alpha

decreases expression

Tacrolimus results in decreased expression of DOC2A mRNA

NCBI chr 1:181,457,415...181,462,528
Ensembl chr 1:181,458,390...181,462,030

G

dedicator of cytokinesis 10

increases expression

Tacrolimus results in increased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525

G

dipeptidylpeptidase 4

increases activity
multiple interactions

Tacrolimus results in increased activity of DPP4 protein
MK0626 inhibits the reaction [Tacrolimus results in increased activity of DPP4 protein]

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

dopamine receptor D2

affects activity
multiple interactions

Tacrolimus affects the activity of DRD2 protein
Sulpiride inhibits the reaction [Tacrolimus affects the activity of DRD2 protein]

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875